Literature DB >> 18925875

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).

Juan M García-Martínez1, Dario R Alessi.   

Abstract

SGK1 (serum- and glucocorticoid-induced protein kinase 1) is a member of the AGC (protein kinase A/protein kinase G/protein kinase C) family of protein kinases and is activated by agonists including growth factors. SGK1 regulates diverse effects of extracellular agonists by phosphorylating regulatory proteins that control cellular processes such as ion transport and growth. Like other AGC family kinases, activation of SGK1 is triggered by phosphorylation of a threonine residue within the T-loop of the kinase domain and a serine residue lying within the C-terminal hydrophobic motif (Ser(422) in SGK1). PDK1 (phosphoinositide-dependent kinase 1) phosphorylates the T-loop of SGK1. The identity of the hydrophobic motif kinase is unclear. Recent work has established that mTORC1 [mTOR (mammalian target of rapamycin) complex 1] phosphorylates the hydrophobic motif of S6K (S6 kinase), whereas mTORC2 (mTOR complex 2) phosphorylates the hydrophobic motif of Akt (also known as protein kinase B). In the present study we demonstrate that SGK1 hydrophobic motif phosphorylation and activity is ablated in knockout fibroblasts possessing mTORC1 activity, but lacking the mTORC2 subunits rictor (rapamycin-insensitive companion of mTOR), Sin1 (stress-activated-protein-kinase-interacting protein 1) or mLST8 (mammalian lethal with SEC13 protein 8). Furthermore, phosphorylation of NDRG1 (N-myc downstream regulated gene 1), a physiological substrate of SGK1, was also abolished in rictor-, Sin1- or mLST8-deficient fibroblasts. mTORC2 immunoprecipitated from wild-type, but not from mLST8- or rictor-knockout cells, phosphorylated SGK1 at Ser(422). Consistent with mTORC1 not regulating SGK1, immunoprecipitated mTORC1 failed to phosphorylate SGK1 at Ser(422), under conditions which it phosphorylated the hydrophobic motif of S6K. Moreover, rapamycin treatment of HEK (human embryonic kidney)-293, MCF-7 or HeLa cells suppressed phosphorylation of S6K, without affecting SGK1 phosphorylation or activation. The findings of the present study indicate that mTORC2, but not mTORC1, plays a vital role in controlling the hydrophobic motif phosphorylation and activity of SGK1. Our findings may explain why in previous studies phosphorylation of substrates, such as FOXO (forkhead box O), that could be regulated by SGK, are reduced in mTORC2-deficient cells. The results of the present study indicate that NDRG1 phosphorylation represents an excellent biomarker for mTORC2 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925875     DOI: 10.1042/BJ20081668

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  444 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

2.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Authors:  Vanessa S Rodrik-Outmezguine; Sarat Chandarlapaty; Nen C Pagano; Poulikos I Poulikakos; Maurizio Scaltriti; Elizabeth Moskatel; José Baselga; Sylvie Guichard; Neal Rosen
Journal:  Cancer Discov       Date:  2011-06-17       Impact factor: 39.397

3.  Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1.

Authors:  Jonathan Brown; Huizhi Wang; Jill Suttles; Dana T Graves; Michael Martin
Journal:  J Biol Chem       Date:  2011-11-01       Impact factor: 5.157

Review 4.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

5.  Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway.

Authors:  Donggon Lyo; Limei Xu; David A Foster
Journal:  Biochem Biophys Res Commun       Date:  2010-05-08       Impact factor: 3.575

Review 6.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

7.  Morphine and cocaine increase serum- and glucocorticoid-inducible kinase 1 activity in the ventral tegmental area.

Authors:  Elizabeth A Heller; Sophia Kaska; Barbara Fallon; Deveroux Ferguson; Pamela J Kennedy; Rachael L Neve; Eric J Nestler; Michelle S Mazei-Robison
Journal:  J Neurochem       Date:  2014-08-26       Impact factor: 5.372

8.  mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Authors:  David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

9.  XPLN is an endogenous inhibitor of mTORC2.

Authors:  Nidhi Khanna; Yimin Fang; Mee-Sup Yoon; Jie Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

Review 10.  The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Tomohiro Suhara; Yuichi Baba; Briana K Shimada; Jason K Higa; Takashi Matsui
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.